Why the study?
What is the role of beta-blockers in the treatment of arterial hypertension according to current guidelines?
What is the role of beta-blockers in the treatment of arterial hypertension according to current guidelines?
The role of beta-blockers as first-line therapy for arterial hypertension remains controversial, with European guidelines maintaining their priority status despite their removal from US and UK guidelines.
Guideline divergence on beta-blockers for hypertension supports individualized decisions; leaves open need for comparative trials to resolve discrepancies.
Beta adrenergic receptor blocking agentsare one of the multi-function classes of the drugs, prescribing to treatvarious cardio-vascular diseases, and at the same time, this class have been mostly discussing for several years due to the number of publications with the critical comments and rule this class of drugs out from priority groups for the treatment of arterial hypertension (AH), as, for example, it took place in the United Kingdom and the United States. However, national guidelines for the diagnosis and treatment of arterial hypertension (AH), as well as the guidelines from the European Society of Hyper- tension keep the same position on the β-blockers, including them on equal ground with list of 5 major classes of antihypertensive drugs to treat AH.
No takes yet. Share an insight, caveat, or question.
Zhernakova et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: